Royce & Associates’s Sutro Biopharma STRO Stock Holding History

Royce & Associates’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-285	Closed	-$26K	–	1176
2019 Q3	$26K	Buy	+285	New	+$28.8K	﹤0.01%	1105

Other funds holding STRO

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates's STRO Position: Q4 2019 in Review

Royce & Associates sold out of Sutro Biopharma (STRO) in Q4 2019, closing a stake of 285 shares — an estimated $26K sold.

Royce & Associates first reported a position in STRO in Q3 2019 and held it in 1 quarter. The position peaked at $26K in Q3 2019. 64 funds tracked by Wall St. Rank hold STRO as of Q4 2019.

Royce & Associates reported no remaining Sutro Biopharma position as of Q4 2019 after selling out during the quarter.
Royce & Associates sold 285 Sutro Biopharma shares in Q4 2019, an estimated $26K.
Royce & Associates first reported a position in Sutro Biopharma in Q3 2019 and held it in 1 quarter.
Royce & Associates's Sutro Biopharma position peaked at $26K in Q3 2019.
64 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2019.

Based on Royce & Associates's 13F filing for Q4 2019, filed 6 Feb 2020.